*SHIRE'S ORNSKOV SAYS PHARMA MERGERS TO CONTINUE *SHIRE CEO SEES M&A CONTINUING, ESPECIALLY IN SPECIALTY PHARMA *SHIRE CEO: SCALE, EFFICIENCY, LACK OF INNOVATION DRIVING DEALS *SHIRE SAYS M&A ALSO DRIVEN BY LOW RATES, EAGER LENDERS
*SHIRE'S ORNSKOV SAYS PHARMA MERGERS TO CONTINUE *SHIRE CEO SEES M&A CONTINUING, ESPECIALLY IN SPECIALTY PHARMA *SHIRE CEO: SCALE, EFFICIENCY, LACK OF INNOVATION DRIVING DEALS *SHIRE SAYS M&A ALSO DRIVEN BY LOW RATES, EAGER LENDERS